Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02488746
Other study ID # FROST
Secondary ID
Status Terminated
Phase N/A
First received June 26, 2015
Last updated December 8, 2016
Start date March 2015
Est. completion date September 2018

Study information

Verified date December 2016
Source Kliniken Ludwigsburg-Bietigheim gGmbH
Contact n/a
Is FDA regulated No
Health authority Federal Institute for Drugs and Medicinal Devices GERMANY:
Study type Observational

Clinical Trial Summary

Prospective observational trial. A full thickness resection of gastric subepithelial tumors is performed after application of full thickness sutures underneath the tumor with the GERDX(TM) device. Hypothesis: This endoscopic method is feasible, effective and safe.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date September 2018
Est. primary completion date September 2018
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- presence of a subepithelial gastric tumor with signs of potential malignancy in endoscopic ultrasound

- age 18 years or older

- participant has given informed consent

Exclusion Criteria:

- tumor size > 40 mm (endosonographic measurement) or large extramural tumor mass

- signs of systemic dissemination of tumor

- current presence of a different neoplastic disease (except after successful curative treatment without continued medication)

- former surgery or disease of esophagus or stomach that impedes insertion of the suturing device

- moribund patient

- limited possibility to give informed consent (e.g. language barrier, psychiatric disease)

- pregnancy and lactation period

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Intervention

Device:
GERDX(TM)
Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.

Locations

Country Name City State
Germany Klinikum Ludwigsburg Ludwigsburg Baden-Württemberg

Sponsors (1)

Lead Sponsor Collaborator
Kliniken Ludwigsburg-Bietigheim gGmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of cases in which a complete macroscopic en bloc resection of the gastric subepithelial tumor could be achieved intraoperative No
Secondary Rate of cases in which a complete microscopic resection of the gastric subepithelial tumor could be achieved within one week after resection (as soon as result of pathologic analysis of resected specimen is available) No
Secondary Rate of complications (bleeding, perforation) 6 months after resection Yes
Secondary Duration of hospitalization within one week after resection No
Secondary Number of participants with local or systemic recidive of tumor 6 months after resection No
Secondary Number of participants with needs of surgical therapy or endoscopic re-resection 6 months after resection No
See also
  Status Clinical Trial Phase
Recruiting NCT05385549 - 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk Phase 2
Recruiting NCT05905887 - Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor Phase 2
Completed NCT01933958 - Regorafenib Post-marketing Surveillance in Japan
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT01440959 - Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 Phase 2
Completed NCT00718562 - Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib Phase 2
Completed NCT00385203 - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). Phase 2
Completed NCT00137449 - Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor Phase 2
Completed NCT00237172 - Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study) Phase 2
Terminated NCT04409223 - Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib Phase 3
Active, not recruiting NCT03556384 - Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST) Phase 2
Recruiting NCT04106024 - Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial Phase 2
Completed NCT02171286 - The Oncopanel Pilot (TOP) Study N/A
Completed NCT01114087 - Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility N/A
Recruiting NCT05366816 - ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST Phase 2
Recruiting NCT03602092 - Observational Registry Data on GIST Patients
Recruiting NCT05197933 - Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach N/A
Completed NCT02931929 - MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT Phase 1/Phase 2
Withdrawn NCT05080621 - Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST) Phase 1/Phase 2
Completed NCT02638766 - Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST Phase 2